Authors
Hossein Ahmadi, Mahdi Mahmoudi, Farhad Gharibdoost, Mahdi Vojdanian, Ahmad Reza Jamshidi, Mohammad Javad Fattahi, Zahra Aghazadeh, Anis Barati, Abbas Mirshafiey
Publication date
2018/2
Journal
Inflammopharmacology
Volume
26
Pages
57-65
Publisher
Springer International Publishing
Description
Objective
This study aimed at investigating the inhibitory effect of β-D-mannuronic acid (M2000) on the Th17 circulating levels and IL-17 a related cytokine in rheumatoid arthritis (RA) patients.
Methods
The study included 27 patients with RA who had failed response to treatment. All patients were treated orally by M2000 at a dose of 500 mg twice daily for 12 weeks (Clinical trial identifier: IRCT2014011213739N2). The patients based on anti-tumor necrosis factor alpha (TNFα) blocker treatment were classified into two groups (conventional group and etanercept group). They were then allowed to continue their treatment excluding non-steroidal anti-inflammatory drugs (NSAIDs). The frequency of circulating Th17 cells and IL-17 serum level were determined before and 12 weeks after M2000 therapy and were compared to the healthy controls by using flow …
Scholar articles
H Ahmadi, M Mahmoudi, F Gharibdoost, M Vojdanian… - Inflammopharmacology, 2018